Evidence-Based Medicine Guidelines
Sirolimus and everolimus for primary immunosuppression in kidney transplant recipients
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Sirolimus and Everolimus for Primary Immunosuppression in Kidney Transplant Recipients." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/456102/all/Sirolimus_and_everolimus_for_primary_immunosuppression_in_kidney_transplant_recipients.
Sirolimus and everolimus for primary immunosuppression in kidney transplant recipients. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/456102/all/Sirolimus_and_everolimus_for_primary_immunosuppression_in_kidney_transplant_recipients. Accessed April 26, 2025.
Sirolimus and everolimus for primary immunosuppression in kidney transplant recipients. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/456102/all/Sirolimus_and_everolimus_for_primary_immunosuppression_in_kidney_transplant_recipients
Sirolimus and Everolimus for Primary Immunosuppression in Kidney Transplant Recipients [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 April 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/456102/all/Sirolimus_and_everolimus_for_primary_immunosuppression_in_kidney_transplant_recipients.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Sirolimus and everolimus for primary immunosuppression in kidney transplant recipients
ID - 456102
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/456102/all/Sirolimus_and_everolimus_for_primary_immunosuppression_in_kidney_transplant_recipients
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
